{"url_path":"/sec/capr/8-k/2026-07-14/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/1133869/0001104659-26-083559-index.html","accession_number":"0001104659-26-083559","cik":"0001133869","ticker":"CAPR","issuer_name":"CAPRICOR THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1133869/0001104659-26-083559-index.html","primary_entity_key":"0001133869","primary_entity_name":"CAPRICOR THERAPEUTICS, INC."},"word_count":355,"has_tables":true,"body_markdown":"CAPRICOR THERAPEUTICS, INC._July 9, 2026\n\n0001133869false00011338692026-07-092026-07-09\n\n​\n\n​\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n​\n\n**FORM****8-K**\n\n​\n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d) of**\n\n**The Securities Exchange Act of 1934**\n\n​\n\nDate of Report (Date of earliest event reported)\n\n​\n\n**July 9, 2026**\n\n​\n\n**CAPRICOR THERAPEUTICS, INC.******\n\n**(Exact name of Registrant as Specified in its Charter)**\n\n​\n\n**  ​ ​ ​**\n\n​\n\n​\n\n**Delaware**\n\n**  ​ ​ ​**\n\n**001-34058**\n\n**  ​ ​ ​**\n\n**88-0363465**\n\n**(State or other jurisdiction********of incorporation)**\n\n​\n\n**(Commission********File Number)**\n\n​\n\n**(I.R.S. Employer********Identification No.)**\n\n​\n\n​\n\n**  ​ ​ ​**\n\n**10865 Road to the Cure, Suite 150****,****San Diego****,****California********(Address of principal executive offices)**\n\n**  ​ ​ ​**\n\n**92121********(Zip Code)**\n\n​\n\n**(****858****)****727-1755**\n\n**(Registrant’s telephone number, including area code)**\n\n​\n\n**Not Applicable**\n\n**(Former name or former address, if changed since last report)**\n\n​\n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n​\n\n☐\n\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n​\n\n☐\n\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n​\n\n☐\n\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n​\n\n☐\n\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n​\n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).\n\n​\n\nEmerging growth company ☐\n\n​\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻\n\n​\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n​\n\n  ​ ​\n\n**Title of Each Class**\n\n**  ​ ​ ​**\n\n**Trading Symbol(s)**\n\n**  ​ ​ ​**\n\n**Name of Each Exchange on Which********Registered**\n\nCommon Stock, par value $0.001 per share\n\nCAPR\n\nThe Nasdaq Global Select Market\n\n​\n\n​\n\n​\n\n​\n\n​"}